KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt RepaymentsR&D In ProcessShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) Short-Term Debt repayments (2016 - 2025)

Historic Short-Term Debt repayments for Pfizer (PFE) over the last 13 years, with Q2 2025 value amounting to $151.0 million.

  • Pfizer's Short-Term Debt repayments fell 9666.22% to $151.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $10.0 billion, marking a year-over-year decrease of 2103.1%. This contributed to the annual value of $11.2 billion for FY2024, which is 37410000.0% up from last year.
  • As of Q2 2025, Pfizer's Short-Term Debt repayments stood at $151.0 million, which was down 9666.22% from $2.0 billion recorded in Q1 2025.
  • Pfizer's Short-Term Debt repayments' 5-year high stood at $7.8 billion during Q3 2024, with a 5-year trough of $1.0 million in Q4 2021.
  • For the 5-year period, Pfizer's Short-Term Debt repayments averaged around $2.3 billion, with its median value being $1.2 billion (2024).
  • Per our database at Business Quant, Pfizer's Short-Term Debt repayments plummeted by 9999.43% in 2021 and then skyrocketed by 38860000.0% in 2022.
  • Pfizer's Short-Term Debt repayments (Quarter) stood at $1.0 million in 2021, then soared by 388600.0% to $3.9 billion in 2022, then crashed by 99.92% to $3.0 million in 2023, then surged by 259033.33% to $7.8 billion in 2024, then crashed by 98.06% to $151.0 million in 2025.
  • Its Short-Term Debt repayments stands at $151.0 million for Q2 2025, versus $2.0 billion for Q1 2025 and $7.8 billion for Q3 2024.